[go: up one dir, main page]

WO2006135121A1 - Composition d’un médicament contre les maladies des os utilisant des plantes médicinales - Google Patents

Composition d’un médicament contre les maladies des os utilisant des plantes médicinales Download PDF

Info

Publication number
WO2006135121A1
WO2006135121A1 PCT/KR2005/001925 KR2005001925W WO2006135121A1 WO 2006135121 A1 WO2006135121 A1 WO 2006135121A1 KR 2005001925 W KR2005001925 W KR 2005001925W WO 2006135121 A1 WO2006135121 A1 WO 2006135121A1
Authority
WO
WIPO (PCT)
Prior art keywords
weight parts
radix
group
bone
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2005/001925
Other languages
English (en)
Inventor
Joon Shik Shin
Young Ock Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2006135121A1 publication Critical patent/WO2006135121A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/32—Bones; Osteocytes; Osteoblasts; Tendons; Tenocytes; Teeth; Odontoblasts; Cartilage; Chondrocytes; Synovial membrane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/284—Atractylodes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/43—Cuscutaceae (Dodder family), e.g. Cuscuta epithymum or greater dodder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/704—Polygonum, e.g. knotweed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A61K36/804—Rehmannia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
    • A61K36/815—Lycium (desert-thorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8969—Polygonatum (Solomon's seal)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9064—Amomum, e.g. round cardamom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Definitions

  • the present invention relates to a pharmaceutical composition for preventing
  • present invention relates to the pharmaceutical composition for preventing and
  • treating bone diseases comprising an extract of the herb medicine mixture as an
  • Atractylodis rhizoma alba at a specific ratio and extracting then, and is effective in
  • osteoporosis preventing and treating bone diseases such as osteoporosis, degenerative bond
  • the bone tissue includes several kinds of bone cells such as osteoprogenitor cells, osteoblasts, osteoclasts and osteocytes. Of them, osteoclasts
  • Osteoblasts are present on the surface of the bone synthesizes and release
  • each oseoblast cell includes a
  • glucocorticoid hormone inhibits the same, leading to the outbreak of osteoporosis.
  • GH growth hormone
  • IGF-I growth hormone
  • TGF-b transforming growth factor-beta
  • FGF FGF, TGF-beta
  • cytokines associated with the development of osteoblast
  • RANK receptor for activator of nuclear factor-kB
  • TNF-alpha ligand for activator of nuclear factor-kB
  • IL- ligand for activator of nuclear factor-kB
  • RANKL RANKL
  • OPG osteoprotegerin
  • cytokines production of such cytokines is inhibited or regulated by hormones directly or
  • Bisphosphonate as a drug inhibiting the bone reabsorption interacts with
  • osteoclasts examples include etidronate and
  • Etidronate induces hyperphosphatemia, but other bisphosphonates
  • Estrogen binds to ER ⁇ (estrogen receptor ⁇ ) or ER ⁇ receptor within an
  • osteoblast is transferred to a nucleus, recognizes ERE ⁇ (estrogen receptor response
  • Droloxifene is to improve raloxifene(Evista) which is important
  • phytoestrogen such as
  • soybean isoflavone soybean isoflavone.
  • phytoestrogen including nonglucosides such as
  • phytoestrogen is co-administered with an
  • osteogenesis activator but there is almost no drug whose effect as an osterogenesis
  • Alendronate which was approved as a therapeutic agent for
  • Bone is not a mere hard tissue but a dynamic tissue being continuously
  • the bone is visibly classified into two groups of an
  • cortex having strong physical activities to protect and support a
  • Osteoporosis is a kind of aging phenomena causing a bone fracture even
  • hyperthyroidism hyperparathyroidism
  • chronic heart failure hyperthyroidism
  • Osteoporosis is medically
  • bone diseases including osteoporosis.
  • medicine extract which is prepared by mixing at least one selected from the group
  • osteoporosis osteoporosis, rheumatoid arthritis
  • present invention can be effectively used for preventing and treating bone diseases.
  • the object of the present invention is to provide a
  • mixed herb medicine extract comprises 100 weight parts of at least one selected from
  • the present invention relates to a pharmaceutical composition for preventing
  • the mixed herb medicine extract comprises 100 weight
  • Trigonellae Semen, Lycii fructus, Dipsaci radix and Atractylodis rhizoma alba Trigonellae Semen, Lycii fructus, Dipsaci radix and Atractylodis rhizoma alba.
  • the present invention relates to a pharmaceutical composition for preventing
  • extract is prepared by mixing at least one selected from the group consisting of black
  • lablab is effective in treating osteoporosis, but in case of using them alone, there is a
  • antler's phospholipids reduce the lipid peroxidation in the brain and liver of an old
  • Achyranthes japonica The naming of Achyranthes japonica is derived from the description of
  • gnarled stem is similar to a knee of a cow. It shows a strong anti-inflammatory analgesic action that is exhibited not through the adrenal cortex but through the
  • Polygoni multiflori radix is in circulation as Asclepiadaceae within the
  • Polygonimitin B and C have been recently isolated therefrom. It shows various characteristics
  • pharmacological actions such as a hemopoietic action, increase in cell number
  • hyperlipidemia insomnia
  • schizophrenia whooping cough
  • ischiadynia malaria and wart.
  • Pehmanniae radix preparata It mainly acts at nasal speculum and pulmonary
  • rhizoma is effective in treating several diseases such as hypertension, coronary
  • Pehmanniae radix preparata is a perennial medicinal herb belonging to
  • Rehmannia glutinos prepared by repeating nine times the procedure of soaking it in
  • medicines selected from the group consisting of antler, Achyranthes japonica,
  • Cuscuta chinensis called also Cuscuta australis is a dried mature
  • Lycii fructus includes betain, zeaxanthin, physalein and vitamins such as
  • cAMP level in senile keeps the balance of cAMP and cGMP ratio, and restores the testosterone level of plasma, which results in fortifying brain function and physical
  • betaine stimulates the regeneration of liver cells and exhibits
  • Trigonellae Semen belongs to Rosales, Leguminosae, and its seed contains a
  • alkaloids proteins and lipids. Since its nature is warm and atoxic, it has been
  • Dipsaci radix which can be substituted with Dipsacus asperoides C.Y., is
  • Atractylodis rhizoma alba which means the root of Atractylodes japonica in
  • the mixed herb medicine may additionally include Liriopis Tuber.
  • soy bean Yak-kong and Dolichos lablab.
  • the mixed herb medicine extract of the present invention is preferably, the mixed herb medicine extract of the present invention
  • the mixed herb medicine extract of the present invention Dipsaci radix based on 100 weight parts of Yak-Kong. More preferably, the mixed herb medicine extract of the present invention
  • Polygonati rhizoma 30 to 50 weight parts of Polygoni multiflori radix, 30 to 50
  • chinensis 50 to 100 weight parts of Lycii fructus and 30 to 50 weight parts of Dipsaci
  • present invention which comprises 30 to 250 weight parts of Achyranthes japonica,
  • the herb medicines described above are mixed with a solvent selected from
  • the extract thus isolated is concentrated under reduced pressure at 40 to
  • the above herb medicines may be powdered, respectively, or
  • present invention can be orally or parenterally administered.
  • medicine extract of the present invention may be formulated into several kinds of
  • the effective ingredient is preferably admixed or
  • a diluent such as a filler, an extender, a binder, a wetting agent, a
  • Solid formulations for oral administration include pills, tablets, dusting powder, granules and capsules. Those solid formulations may be prepared by
  • excipients e. g., starch, calcium carbonate, sucrose, lactose and
  • magnesium stearate and talc may be included in the present formulation.
  • formulations for oral administration include suspension, solution, emulsion and
  • Those formulations may contain a wetting agent, a sweetener, an aromatic hydrocarbonate, a carboxylate, a sulfonate, a sulfonate, a sulfonate, a sulfonate, a sulfonate, a sulfonate, a sulfonate, a sulfonate, a sulfonate, sorbitol syrup.
  • Those formulations may contain a wetting agent, a sweetener, an aromatic
  • Formulations for parenteral administration include a sterilized aqueous
  • Water-insoluble excipients and suspending agents comprise
  • vegetable fats such as propylene glycol, polyethylene glycol and olive oil, and
  • esters such as ethyl oleate.
  • Witepsol ® Macrogol ® , Tween ® 61, cacao fats,
  • laurin fats and glycerogelatins may be used as bases of suppositories.
  • composition may range from about 10 to 500 mg/kg body weight,
  • the present invention includes a heath food comprising the mixed
  • bone diseases osteoporosis, rheumatoid arthritis
  • degenerative bond diseases osteoporosis, rheumatoid arthritis
  • health food used herein refers to a food prepared by adding the
  • Fig. Ia shows a cross-section of a thighbone tissue of a white mouse without
  • Fig. Ib shows a cross-section of a thighbone tissue of a white mouse
  • Example 1 administered with a water extract prepared in Example 1.
  • Fig. 2a shows a cross-section of a thighbone tissue of a sham group having no
  • Fig. 2b shows a cross-section of a thighbone tissue of a white mouse administered with a positive control (Libial).
  • Fig. 3 shows a graph comparing the change in bone density of an
  • Example 1 water extract of Example 1 to the white mouse to that of a sham group having no
  • multiflori radix 40 g Polygonati rhizoma 40 g and Pehmanniae radix preparata 40 g
  • water extract (hereinafter, referred to as "water extract").
  • composition of the present invention is a composition of the present invention.
  • Yak-kong 90 g Achyranthes japonica 90 g, antler 90 g, Cuscuta chinensis 60 g,
  • Lycii fructus 60 g Trigonellae semen 30 g, Dipsaci radix 30 g, Polygoni multiflori
  • Lycii fructus 40 g Trigonellae semen 20 g, Dipsaci radix 20 g, Polygoni multiflori
  • multiflori radix 40 g Polygonati rhizoma 40 g, Pehmanniae radix preparata 40 g,
  • Amomi semen 20 g and Atractylodis rhizoma alba 40 g were extracted with water using the same method as described in Example 1.
  • Trigonellae semen 40 g Trigonellae semen 40 g, Dipsaci radix 40 g, Polygoni multiflori radix 40 g and
  • multiflori radix 40 g Polygonati rhizoma 40, Pehmanniae radix preparata 40 g,
  • Atractylodis rhizoma alba 40 g and Liriopis tuber 40 g were powderized, and then,
  • MG-63 cell line having a property similar to that of an osteoblast, which is a
  • MG-63 cells were inoculated into DMEM (Gibco BRL, USA) supplemented
  • agent for osteoporosis was a comparative group for MG-63 cell line.
  • Formazan crystals generated therefrom were dissolved in DMSO and measured its absorbance at 550 nm with an ELISA reader.
  • a cell proliferation rate (%) was calculated as a ratio (%) of the absorbance of
  • present invention exerts a high proliferation rate to the osteoblast-like cells such as
  • present invention on the osteoblast proliferation, it showed a high proliferation
  • the collected femoral bone tissue was fixed in a 10% formalin solution and
  • paraffin embedding After paraffin-embedded bone tissue was sliced
  • H&E hematoxyline and eosin
  • invention can be effectively used for preventing and treating osteoporosis.
  • mice receiving no treatment for 8 weeks after ovariectomy both mice receiving no treatment for 8 weeks after ovariectomy.
  • Examples 1 to 3 Examples 1 to 3 was suspended in 0.5% methylcellulose solution,
  • mice were observed in
  • BMD bone mineral density
  • BMC bone mineral density
  • the mixed herb medicine extract of the present invention (10 g) was mixed
  • the mixture was filled into a No. 5 gelatin capsule by using a proper
  • the mixed herb medicine extract of the present invention (10 mg) was mixed
  • the mixed herb medicine extract of the present invention Based on a daily dose, the mixed herb medicine extract of the present invention
  • vitamin A, vitamin Bl and vitamin B2 were mixed to prepare a health food.
  • the mixed herb medicine extract of the present invention As described above, the mixed herb medicine extract of the present invention
  • extract of the present invention does not show any toxicity, it is expected to be used

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne une composition pharmaceutique pour la prévention et le traitement de maladies des os qui utilise un mélange de plantes médicinales. En particulier, la présente invention concerne une composition pharmaceutique pour la prévention et le traitement de maladies des os qui comprend un extrait d’un mélange de plantes médicinales comme ingrédient actif, où l'extrait est préparé en mélangeant au moins un élément sélectionné parmi le groupe constitué par la fève noire, la fève soja, le Yak-kong (Rhynchosia nolubilis) et le dolique d'Égypte ; au moins trois éléments sélectionnés parmi le groupe constitué par le bois de cerf, l'Achyranthes japonica, la Pehmanniae radix preparata, La Polygonati rhizoma, l'Amorni semen et la Polygoni multiflori radix; et au moins deux éléments sélectionnés parmi le groupe constitué par du Cuscuta chinensis, du Trigonellae Semen, du Lycii fructus, du Dipsaci radix et de l’Atractylodis rhizoma alba, dans un rapport spécifique et leur extraction, et est efficace pour empêcher et traiter les maladies des os telles l'ostéoporose, les maladies dégénératives des os et l'arthrite rhumatoïde.
PCT/KR2005/001925 2005-06-17 2005-06-21 Composition d’un médicament contre les maladies des os utilisant des plantes médicinales Ceased WO2006135121A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2005-0052513 2005-06-17
KR1020050052513A KR100585445B1 (ko) 2005-06-17 2005-06-17 혼합 생약재를 이용한 골질환 예방 및 치료용 약제 조성물

Publications (1)

Publication Number Publication Date
WO2006135121A1 true WO2006135121A1 (fr) 2006-12-21

Family

ID=37182197

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2005/001925 Ceased WO2006135121A1 (fr) 2005-06-17 2005-06-21 Composition d’un médicament contre les maladies des os utilisant des plantes médicinales

Country Status (2)

Country Link
KR (1) KR100585445B1 (fr)
WO (1) WO2006135121A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111905056A (zh) * 2020-09-09 2020-11-10 御元堂药业股份有限公司 一种治疗风湿、类风湿及各种骨病的中药组方
CN114949079A (zh) * 2022-08-02 2022-08-30 吉林瑞隆药业有限责任公司 一种用于骨质疏松的药物组合物及其制备方法
CN115710320A (zh) * 2022-11-23 2023-02-24 安徽中医药大学 一种预防和/或治疗自身免疫疾病的黄精多糖

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101059332B1 (ko) * 2008-02-29 2011-08-24 대구한의대학교산학협력단 홍화자, 숙지황 및 사인의 혼합생약 추출물을 유효성분으로함유하는 골다공증질환의 예방 및 치료용 조성물
KR101451754B1 (ko) 2013-08-05 2014-10-16 동우당제약(주) 지골피와 속단의 혼합 추출물을 함유하는 골대사 질환 예방 및 골 기능 개선을 위한 조성물
KR101992686B1 (ko) 2018-06-21 2019-09-27 이차범 체력 및 관절건강 증진을 위한 생약농축고 제조방법
KR102321579B1 (ko) * 2019-09-30 2021-11-05 한국 한의학 연구원 Kiom 법하수오 추출물을 유효성분으로 포함하는 골다공증의 예방, 개선 또는 치료용 조성물
CN113170883A (zh) * 2021-04-26 2021-07-27 吉林大清鹿苑保健科技有限公司 一种增加骨密度的保健食品及其制备方法

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000053988A (ko) * 2000-05-16 2000-09-05 신준식 구성약제의 골다공증 및 류마티스 관절염 치료를 위한물추출물 및 추출방법
KR20020052034A (ko) * 2000-12-23 2002-07-02 신준식 오적골, 우슬, 두충, 오가피, 고비 및 구판을 주성분으로함유하는 의약조성물 및 이를 주성분으로 함유한 약학적제제
KR100345752B1 (ko) * 2000-06-03 2002-07-27 신준식 구성약제의 골다공증과 퇴행성 골질환 및 류마티스 관절염치료를 위한 물추출물 및 추출방법
KR20030031418A (ko) * 2001-10-10 2003-04-21 한국 한의학 연구원 혼합 생약재 추출물 및 이를 포함하는 골다공증 예방 또는치료용 약학적 조성물
KR100382040B1 (en) * 2002-08-06 2003-04-26 Naturalendo Tech Co Ltd Composition for stimulating estrogen secretion and regenerating female reproductive tissue cells
KR20030044973A (ko) * 2003-05-16 2003-06-09 황규현 신경통, 관절염, 골다공증 예방식품 제조방법
KR100394147B1 (ko) * 2000-06-03 2003-08-09 신준식 구성약제의 만성골다공증 및 류마티스 관절염 치료를 위한물추출물 및 추출방법
CN1440790A (zh) * 2003-04-02 2003-09-10 山东省中医药研究院 苍术油在制备治疗骨质疏松症药物中的应用
JP2004067590A (ja) * 2002-08-06 2004-03-04 Naris Cosmetics Co Ltd 女性ホルモン産生促進剤及びこれを含有する皮膚外用剤
KR100472408B1 (ko) * 2001-11-22 2005-03-08 주식회사 싸이클로젠 골다공증 치료용 생약조성물의 제조방법
KR20050047579A (ko) * 2003-11-18 2005-05-23 신준식 혼합생약재를 이용한 골질환 예방 및 치료용 약제 조성물

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000053988A (ko) * 2000-05-16 2000-09-05 신준식 구성약제의 골다공증 및 류마티스 관절염 치료를 위한물추출물 및 추출방법
KR100415815B1 (ko) * 2000-05-16 2004-01-31 신준식 우슬, 오공, 두충, 오가피, 방풍을 주성분으로 함유하는의약 조성물 및 이를 주성분으로 함유하는 약학적 제제
KR100345752B1 (ko) * 2000-06-03 2002-07-27 신준식 구성약제의 골다공증과 퇴행성 골질환 및 류마티스 관절염치료를 위한 물추출물 및 추출방법
KR100394147B1 (ko) * 2000-06-03 2003-08-09 신준식 구성약제의 만성골다공증 및 류마티스 관절염 치료를 위한물추출물 및 추출방법
KR20020052034A (ko) * 2000-12-23 2002-07-02 신준식 오적골, 우슬, 두충, 오가피, 고비 및 구판을 주성분으로함유하는 의약조성물 및 이를 주성분으로 함유한 약학적제제
KR20030031418A (ko) * 2001-10-10 2003-04-21 한국 한의학 연구원 혼합 생약재 추출물 및 이를 포함하는 골다공증 예방 또는치료용 약학적 조성물
KR100472408B1 (ko) * 2001-11-22 2005-03-08 주식회사 싸이클로젠 골다공증 치료용 생약조성물의 제조방법
KR100382040B1 (en) * 2002-08-06 2003-04-26 Naturalendo Tech Co Ltd Composition for stimulating estrogen secretion and regenerating female reproductive tissue cells
JP2004067590A (ja) * 2002-08-06 2004-03-04 Naris Cosmetics Co Ltd 女性ホルモン産生促進剤及びこれを含有する皮膚外用剤
CN1440790A (zh) * 2003-04-02 2003-09-10 山东省中医药研究院 苍术油在制备治疗骨质疏松症药物中的应用
KR20030044973A (ko) * 2003-05-16 2003-06-09 황규현 신경통, 관절염, 골다공증 예방식품 제조방법
KR20050047579A (ko) * 2003-11-18 2005-05-23 신준식 혼합생약재를 이용한 골질환 예방 및 치료용 약제 조성물

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111905056A (zh) * 2020-09-09 2020-11-10 御元堂药业股份有限公司 一种治疗风湿、类风湿及各种骨病的中药组方
CN114949079A (zh) * 2022-08-02 2022-08-30 吉林瑞隆药业有限责任公司 一种用于骨质疏松的药物组合物及其制备方法
CN115710320A (zh) * 2022-11-23 2023-02-24 安徽中医药大学 一种预防和/或治疗自身免疫疾病的黄精多糖
CN115710320B (zh) * 2022-11-23 2023-10-24 安徽中医药大学 一种预防和/或治疗自身免疫疾病的黄精多糖

Also Published As

Publication number Publication date
KR100585445B1 (ko) 2006-06-07

Similar Documents

Publication Publication Date Title
KR100645385B1 (ko) 비만 억제용 조성물
KR100877604B1 (ko) 가공인삼 추출물을 함유하는 비만의 예방 및 치료용조성물
KR100980819B1 (ko) 복합생약 추출물을 유효성분으로 함유하는 조성물 및 이의제조방법
WO2008069636A1 (fr) Composition stimulant la croissance osseuse contenant comme principe actif un complexe d'extraits de médicaments crus
US7763284B2 (en) Method for treating or preventing symptoms associated with menopause
KR101177508B1 (ko) 폐경기 여성건강 예방 및 치료용 칡 추출물 조성물
US9974822B2 (en) Composition containing composite extract of rehmannia glutinosa and pueraria lobata for preventing or treating menopausal symptoms
KR100456981B1 (ko) 식물추출물을 포함하는 골다공증 예방 또는 치료용 조성물및 그 제조 방법
EP1583547B1 (fr) Ingredients anti-obesite obtenus a partir de plantes medicinales et leur composition
WO2006135121A1 (fr) Composition d’un médicament contre les maladies des os utilisant des plantes médicinales
US8333998B2 (en) Herbal mixture extract of rehmanniae radix preparata and acanthopanacis cortex and a composition comprising the same for prevention and treatment of osteoporosis
RU2145232C1 (ru) Средство лечения миомы матки, как гормонально-зависимой опухоли, и способ его осуществления
CN102028751B (zh) 用作植物雌激素的中药组合物及其用途
KR20210133909A (ko) 함초 추출물을 포함하는 골 질환 또는 갱년기 질환의 예방 또는 치료용 조성물
KR101917363B1 (ko) 콩 발아배아 추출물을 포함하는 여성 갱년기 질환의 예방 또는 치료용 약학조성물
KR101895972B1 (ko) 번행초 추출물을 포함하는 갱년기 장애의 예방 또는 치료용 조성물
KR101193540B1 (ko) 황기，계지 및 황백의 혼합생약재 추출물을 포함하는 골다공증 및 골질환 예방 및 치료용 조성물
CN105012853A (zh) 一种治疗子宫肌瘤的中药组合物及其制备方法和用途
US20040191344A1 (en) Pharmaceutical composition for prophylaxis or treatment of osteoporosis, and method to prepare the same
KR100703180B1 (ko) 혼합 생약제 추출물을 포함하는 골다공증 질환의 예방 및치료를 위한 약학조성물
US11517602B2 (en) Traditional Chinese medicine composition for improving bone health and preparation and uses thereof
US10286025B2 (en) Composition comprising combined extracts of Schisandra fructus, Eucommiae cortex and Lycii fructus for preventing or treating metabolic bone diseases
CN108743800A (zh) 一种用于治疗心脑血管的中药粉
KR100404455B1 (ko) 성장촉진추출물 및 이를 함유하는 약학적 제제
WO2008007880A1 (fr) Composition comprenant un extrait de prunus persica (l.) batsch traitant et prévenant les maladies osseuses.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05756854

Country of ref document: EP

Kind code of ref document: A1